Sandoz's Erelzi (etanercept- biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults
Shots:
- The approval is based on P-III EGALITY study results assessing Erelzi (etanercept) vs Enbrel- evaluating its PK- safety and efficacy
- On 17 Jan- 2019 Sandoz received NOC from Health Canada for Erelzi for reducing signs and symptoms- inhibiting the progression of structural damage of active arthritis & improving physical function in adults with PsA- in combination with methotrexate who do not respond to methotrexate as monothx
- Erelzi (etanercept- biosimilar) is a mAb- available as a pre-filled syringe (PFS) & pre-filled pen (PFP) in 25 mg and 50 mg PFS- approved by Health Canada for moderately to severely active RA & reducing signs and symptoms of moderately to severely active polyarticular JIA in April- 2017
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
